Ixekizumab 伊西贝单抗; LY2439821,98.90%
产品编号:Bellancom-P9924| CAS NO:1143503-69-8
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Ixekizumab 伊西贝单抗; LY2439821
产品介绍 | Ixekizumab 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A (KD<3 pM)。Ixekizumab 直接阻断IL-17A与IL-17RA的结合,但不与其他IL-17家族成员结合。Ixekizumab 用于中重度斑块型银屑病的研究。 | ||||||||
---|---|---|---|---|---|---|---|---|---|
生物活性 | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis. | ||||||||
体外研究 |
The equilibrium KD of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (KD of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||
体内研究 |
Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
体内研究 |
Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
性状 | Liquid | ||||||||
溶解性数据 | |||||||||
运输条件 | |||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||
参考文献 |
|